Prevalence of Prostate Cancer in Men with Hematuria

What is it about?

The study analyzed the prevalence of prostate cancer in men attending evaluation for hematuria. The systematic search included 65 studies and a meta-analysis was performed on 42 studies. The prevalence of prostate cancer was found to be 3.0% (2.0-4.1%) in men with hematuria, with a higher prevalence in men with macrohematuria (5.9%) compared to those with microhematuria (1.4%). The findings suggest that a digital rectal examination and prostate-specific antigen measurement should become a standard procedure for all men with hematuria, especially for men with macrohematuria.

Featured Image

Why is it important?

This research is important because it investigates the prevalence of prostate cancer in men attending evaluation for hematuria. This information is crucial for healthcare providers to determine whether men with hematuria should have prostate examinations performed. Early detection of prostate cancer is essential for effective treatment and improved patient outcomes. Key Takeaways: 1. The prevalence of prostate cancer is considerable in men attending evaluation for hematuria, with a pooled prevalence of 3.0% (2.0-4.1%). 2. A digital rectal examination and prostate-specific antigen measurement should become a standard procedure for all men with hematuria, especially for men with macroscopic hematuria. 3. Previous studies have shown a significant difference in cancer prevalence between individuals with macro- and microhaematuria. Therefore, guidelines on evaluation of hematuria should consider including diagnostic tests for prostate cancer.